Clinical TrialsEnrollment completed in Phase 2 program, indicating progress in clinical development.
Intellectual PropertyChinese patent claims allowed, covering Allocetra application in treatment of osteoarthritis, providing added intellectual property protection in China through at least 2040.
Price TargetReiteration of Buy rating while raising the 12-month price target to $7 from $6.